STAT

Buried in Trump’s executive order on drug pricing is a windfall clause for pharma

The pharmaceutical industry could see windfall profits from a little-noticed tweak to the insurance market tucked into the Trump administration’s draft executive order on drug prices, experts say.

The short, technical paragraph calls for the Internal Revenue Service to allow patients with high-deductible health plans to receive care for chronic diseases, including drugs, before meeting their deductibles.

This allowance, known as a “safe harbor,” could be welcome news for patients with chronic conditions like diabetes or asthma stuck with skimpy plans. For example, a diabetes patient could fill her prescription for insulin with just

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Opinion: It’s Time To Change The Definition Of ‘Health’
Rather than pursuing the "absence" of disease, we need a more inclusive definition of health — one that works for more people.
STAT4 min read
Opinion: State Drug Importation Programs Will Work With The FDA, Not Outside Of It
State programs can use the global pharmaceutical supply chain to relieve the sometimes crushing financial burden of drug treatments — at least until we have an effective national approach to…
STAT5 min readSociety
Opinion: I Wanted To Try Medical Marijuana. Why Couldn’t My Doctors Help Me?
Until we make it easier to study the effects of #medicalmarijuana and #cannabis, and train doctors about its benefits and risks, people who could benefit from it will continue to…